Graphical RepresentationClick to download graphical representation template
Terje Svingen; National Food Institute, Technical University of Denmark, Kongens Lyngby, 2800 Denmark
Point of Contact
Terje Svingen (email point of contact)
- Terje Svingen
|Author status||OECD status||OECD project||SAAOP status|
|Under development: Not open for comment. Do not cite|
This AOP was last modified on August 30, 2019 04:34
|Antagonism, Androgen receptor||December 03, 2016 16:37|
|Decrease, androgen receptors (AR) activation||April 10, 2019 05:24|
|decrease, transcription of genes by AR||August 30, 2019 04:19|
|decrease, male anogenital distance||August 31, 2019 12:07|
This AOP links Androgen receptor antagonism during fetal life with short anogenital distance (AGD) in male offspring. A short AGD around birth is a marker for feminization of male fetuses and is associated with male reproductive disorders, including reduced fertility in adulthood. Although a short AGD is not necessarily ‘adverse’ from a human health perspective, it is considered an ‘adverse outcome’ in OECD test guidelines; AGD measurements are mandatory in specific tests for developmental and reproductive toxicity in chemical risk assessment (TG 443, TG 421/422, TG 414).
The AR is a nuclear receptor involved in the transcriptional regulation of various target genes during development and adulthood across species. Its main ligand is testosterone and dihydrotestosterone (DHT). Under normal physiological conditions, testosterone produced mainly by the testicles, is converted in peripheral tissues by 5α-reductase into DHT, which in turn binds AR and activates downstream target genes. AR signaling is necessary for normal masculinization of the developing fetus, including differentiation of the levator ani/bulbocavernosus (LABC) muscle complex in male fetuses. The LABC complex does not develop in the absence, or low levels of, androgen signaling, as in female fetuses.
The key events in this pathway is antagonism of the AR in target cells of the primitive perineal region, which leads to inactivation of the AR and failure to properly masculinize the perineum/LABC complex. In this instance, the local levels of testosterone or DHT may be normal, but prevented from binding the AR.
Summary of the AOP
Events: Molecular Initiating Events (MIE)
|Sequence||Type||Event ID||Title||Short name|
|MIE||26||Antagonism, Androgen receptor||Antagonism, Androgen receptor|
|KE||1614||Decrease, androgen receptors (AR) activation||Decrease, AR activation|
|KE||1687||decrease, transcription of genes by AR||decrease, transcription of genes by AR|
|AO||1688||decrease, male anogenital distance||short male AGD|
Relationships Between Two Key Events
(Including MIEs and AOs)
Life Stage Applicability
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Considerations for Potential Applications of the AOP (optional)
1. Schwartz CL, Christiansen S, Vinggaard AM, Axelstad M, Hass U and Svingen T (2019), Anogenital distance as a toxicological or clinical marker for fetal androgen action and risk for reproductive disorders. Arch Toxicol 93: 253-272.